Kanya Rajangam

CIK: 0001816676

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SNTI

Senti Biosciences Holdings, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

SNTI
Senti Biosciences Holdings, Inc.
Oct 21, 2026
Tax Payment(F)
Direct
20K shares-
SNTI
Senti Biosciences, Inc.
Mar 9, 2026
Tax Payment(F)
Direct
10.8K shares-
SNTI
Senti Biosciences, Inc.
Feb 2, 2026
Tax Payment(F)
Direct
1.4K shares-
SNTI
Senti Biosciences, Inc.
Mar 10, 2025
Conversion(C)
Indirect
33K shares at avg. $2.25$74K
SNTI
Senti Biosciences, Inc.
Mar 7, 2025
Award(A)
Direct
78.4K shares-
SNTI
Senti Biosciences, Inc.
Mar 6, 2025
Award(A)
Stock Option (Right to Buy)
Direct
235.1K shares-
SNTI
Senti Biosciences, Inc.
Feb 6, 2025
Sale(S)
Direct
182 shares at avg. $4.37$795.34
SNTI
Senti Biosciences, Inc.
Feb 4, 2025
Sale(S)
Direct
1.3K shares at avg. $4.07$5K
SNTI
Senti Biosciences, Inc.
Dec 9, 2024
Award(A)
Series A Convertible Preferred Stock
Indirect
33 shares at avg. $2250.00-
SNTI
Senti Biosciences, Inc.
Dec 9, 2024
Award(A)
Common Stock Warrant (right to buy)
Indirect
49.5K shares-

		Type	Shares	Price		Ownership
Oct 21, 2026	SNTI Senti Biosciences Holdings, Inc.	Tax Payment(F)	19,953	-	$0	Direct
Mar 9, 2026	SNTI Senti Biosciences, Inc.	Tax Payment(F)	10,757	-	$0	Direct
Feb 2, 2026	SNTI Senti Biosciences, Inc.	Tax Payment(F)	1,384	-	$0	Direct
Mar 10, 2025	SNTI Senti Biosciences, Inc.	Conversion(C)	33,000	$2.25	$74,250	Indirect
Mar 7, 2025	SNTI Senti Biosciences, Inc.	Award(A)	78,363	-	-	Direct
Mar 6, 2025	SNTI Senti Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	235,088	-	-	Direct
Feb 6, 2025	SNTI Senti Biosciences, Inc.	Sale(S)	182	$4.37	$795	Direct
Feb 4, 2025	SNTI Senti Biosciences, Inc.	Sale(S)	1,297	$4.07	$5,279	Direct
Dec 9, 2024	SNTI Senti Biosciences, Inc.	Award(A) Series A Convertible Preferred Stock	33	$2250.00	-	Indirect
Dec 9, 2024	SNTI Senti Biosciences, Inc.	Award(A) Common Stock Warrant (right to buy)	49,500	-	-	Indirect

1-10 of 10 transactions

About Rajangam Kanya

Rajangam Kanya (SEC CIK 0001816676) files insider reports with the SEC as Pres. & Chief Med. & Dev. Off. of Senti Biosciences Holdings, Inc. (SNTI).

Signal8 holds 7 ownership filings by Rajangam Kanya, all Form 4s, filed between Dec 10, 2024 and Oct 23, 2026. Those filings report 10 transactions, from Dec 9, 2024 to Oct 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rajangam Kanya's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Rajangam Kanya

Oct 21, 2026: Tax withholding of SNTI shares (Form 4, code F).
Mar 9, 2026: Tax withholding of SNTI shares (Form 4, code F).
Feb 2, 2026: Tax withholding of SNTI shares (Form 4, code F).
Mar 10, 2025: Conversion of SNTI shares (Form 4, code C).
Mar 7, 2025: Grant or award of SNTI shares (Form 4, code A).

Other insiders filing for Senti Biosciences Holdings, Inc. (SNTI)

Lu Timothy K, CEO
Baum Bryan Daniel, Director
Collins James J., Director
Hsiung Feng, Director
Schulz Fran, Director
COOPERSTONE BRENDA, Director

How to read Form 4 transaction codes